24Mar/14

Greater Effect on Disability Remains the Top Opportunity in Relapsing … – PR Newswire (press release)

Greater Effect on Disability Remains the Top Opportunity in Relapsing
PR Newswire (press release)
Clinical data and the opinions of interviewed thought leaders indicate that Lemtrada, Biogen Idec/AbbVie’s daclizumab, and Roche/Genentech’s ocrelizumab offer improvements in ARR over first-line injectable mainstays (e.g., Teva’s Copaxone). Surveyed …

and more »

19Mar/14

Biogen Faces Delay in FDA Action Date – Analyst Blog – NASDAQ


The Utah People’s Post
Biogen Faces Delay in FDA Action Date – Analyst Blog
NASDAQ
In addition to Plegridy, Biogen has daclizumab in its MS pipeline. Biogen and partner AbbVie ( ABBV ) are conducting a two-year phase III study (DECIDE) on daclizumab with results due later this year. Biogen is also looking to expand Tysabri’s label
Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar FutureWallStreetPR

all 30 news articles »

19Mar/14

Biogen Faces Delay in FDA Action Date – Zacks.com


Science World Report
Biogen Faces Delay in FDA Action Date
Zacks.com
Biogen is also looking to expand Tysabri’s label and is conducting a phase IIIb study (ASCEND) in combination with daclizumab in patients with secondary-progressive MS – results are expected in 2015. The delay in Plegridy’s approval date should not be
Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar FutureWallStreetPR

all 28 news articles »

12Mar/14

Interleukin-Antagonisten: Hoch effektiv gegen Entzündungen – Pharmazeutische Zeitung online

Interleukin-Antagonisten: Hoch effektiv gegen Entzündungen
Pharmazeutische Zeitung online
eines Transplantats innerhalb der ersten zehn Tage nach der Operation sind vor allem die zytotoxischen T-Lymphozyten verantwortlich. In Kombination mit anderen Immunsuppressiva soll Basiliximab die Abstoßung einer transplantierten Niere verhindern.

and more »

06Mar/14

BMO Capital Upgrades Biogen (BIIB) to Outperform – StreetInsider.com (subscription)

BMO Capital Upgrades Biogen (BIIB) to Outperform
StreetInsider.com (subscription)
“With additional opportunities over the next 12 months for proof-of- concept with anti-LINGO for remyelination, TYSABRI in secondary progressive MS (SPMS), daclizumab in relapsing and remitting MS (RRMS), BIIB037 in Alzheimer’s, STX-100 in idiopathic 

and more »